Clonixin

Identification

Name
Clonixin
Accession Number
DB09218
Type
Small Molecule
Groups
Approved
Description

Clonixin is a non-steroidal anti-inflammatory drug. It also has analgesic, antipyretic, and platelet-inhibitory actions.

Structure
Thumb
Synonyms
Not Available
External IDs
CBA 93626 / SCH-10304
Categories
UNII
V7DXN0M42R
CAS number
17737-65-4
Weight
Average: 262.69
Monoisotopic: 262.0509053
Chemical Formula
C13H11ClN2O2
InChI Key
CLOMYZFHNHFSIQ-UHFFFAOYSA-N
InChI
InChI=1S/C13H11ClN2O2/c1-8-10(14)5-2-6-11(8)16-12-9(13(17)18)4-3-7-15-12/h2-7H,1H3,(H,15,16)(H,17,18)
IUPAC Name
2-[(3-chloro-2-methylphenyl)amino]pyridine-3-carboxylic acid
SMILES
CC1=C(NC2=C(C=CC=N2)C(O)=O)C=CC=C1Cl

Pharmacology

Indication

Used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation.

Structured Indications
Not Available
Pharmacodynamics

Clonixin is a non-steroidal anti-inflammatory drug (NSAID) similar in structure to Diclofenac. It produces vasodilation and analgesia.

Mechanism of action

The mechanism of clonixin does not appear to have been investigated on a molecular level. It is presumed to function similarly to other NSAIDs by inhibiting cycloxygenase enzymes 1 and 2 resulting in a reduction in prostaglandin production.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Clonixin is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Clonixin is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Clonixin is combined with 5-androstenedione.Experimental, Illicit
AbciximabClonixin may increase the anticoagulant activities of Abciximab.Approved
AcebutololClonixin may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Clonixin.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Clonixin is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolClonixin may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Clonixin.Approved, Vet Approved
AclarubicinClonixin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Clonixin.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Clonixin is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Clonixin is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Clonixin is combined with Aldosterone.Experimental, Investigational
AldoxorubicinClonixin may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Clonixin is combined with Alendronic acid.Approved
AliskirenClonixin may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Clonixin is combined with Alminoprofen.Experimental
AlprenololClonixin may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Clonixin.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Clonixin is combined with Amcinonide.Approved
AmikacinClonixin may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideClonixin may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinClonixin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodClonixin may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Clonixin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Clonixin is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Clonixin is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Clonixin is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Clonixin is combined with Anisodamine.Investigational
AnnamycinClonixin may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Clonixin.Approved
Antithrombin III humanClonixin may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanClonixin may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Clonixin is combined with Apocynin.Investigational
ApramycinClonixin may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Clonixin.Approved, Investigational
ArbekacinClonixin may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinClonixin may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanClonixin may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololClonixin may decrease the antihypertensive activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Clonixin is combined with Atamestane.Investigational
AtenololClonixin may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Clonixin.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Clonixin.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Clonixin.Approved
BalsalazideClonixin may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminClonixin may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Clonixin is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololClonixin may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinClonixin may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Clonixin.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Clonixin is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Clonixin.Approved
BenorilateThe risk or severity of adverse effects can be increased when Clonixin is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Clonixin.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Clonixin is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Clonixin.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Clonixin is combined with Betamethasone.Approved, Vet Approved
BetaxololClonixin may decrease the antihypertensive activities of Betaxolol.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Clonixin.Approved, Investigational
BevantololClonixin may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Clonixin is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Clonixin.Approved, Investigational
BisoprololClonixin may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinClonixin may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololClonixin may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Clonixin.Approved
BucillamineThe risk or severity of adverse effects can be increased when Clonixin is combined with Bucillamine.Investigational
BucindololClonixin may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Clonixin is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Clonixin is combined with Bufexamac.Experimental
BufuralolClonixin may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Clonixin is combined with Bumadizone.Experimental
BumetanideClonixin may decrease the diuretic activities of Bumetanide.Approved
BupranololClonixin may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Clonixin.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Clonixin.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Clonixin.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Clonixin.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Clonixin is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Clonixin.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Clonixin.Approved, Vet Approved, Withdrawn
CarteololClonixin may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolClonixin may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Clonixin.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Clonixin.Approved, Investigational
CeliprololClonixin may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinClonixin may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Clonixin.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Clonixin.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Clonixin.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Clonixin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Clonixin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Clonixin is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Clonixin.Approved
CinoxacinClonixin may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidClonixin may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clonixin is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clonixin is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clonixin is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clonixin is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Clonixin is combined with Clodronic Acid.Approved, Investigational, Vet Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Clonixin.Vet Approved
CloranololClonixin may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Clonixin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Clonixin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Clonixin is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Clonixin is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Clonixin is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Clonixin is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Clonixin.Experimental
CyclosporineClonixin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateClonixin may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinClonixin may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidClonixin may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanClonixin may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinClonixin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Clonixin is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Clonixin is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Clonixin.Experimental
DesirudinClonixin may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Clonixin is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Clonixin is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Clonixin is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Clonixin is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Clonixin is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Clonixin is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Clonixin is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Clonixin.Approved, Investigational
DextranClonixin may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Clonixin may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Clonixin may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Clonixin may increase the anticoagulant activities of Dextran 75.Approved
DibekacinClonixin may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Clonixin.Approved, Vet Approved
DicoumarolClonixin may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Clonixin is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Clonixin is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clonixin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Clonixin is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Clonixin is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Clonixin.Approved
DihydrostreptomycinClonixin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Clonixin.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Clonixin.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Clonixin.Approved
DoxorubicinClonixin may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneClonixin may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Clonixin.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Clonixin is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Clonixin is combined with E-6201.Investigational
Edetic AcidClonixin may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanClonixin may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Clonixin.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Clonixin.Approved
EnoxacinClonixin may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinClonixin may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Clonixin.Experimental
EpanololClonixin may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Clonixin.Approved
EpirubicinClonixin may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneClonixin may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Clonixin.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Clonixin.Approved
EquileninThe risk or severity of adverse effects can be increased when Clonixin is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Clonixin is combined with Equilin.Approved
EsmololClonixin may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Clonixin is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Clonixin is combined with Estrone sulfate.Approved
Etacrynic acidClonixin may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Clonixin.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Clonixin is combined with Ethenzamide.Experimental
Ethyl biscoumacetateClonixin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Clonixin is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Clonixin.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Clonixin.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Clonixin.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Clonixin is combined with Evening primrose oil.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Clonixin.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Clonixin.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Clonixin.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Clonixin.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Clonixin.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Clonixin is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Clonixin is combined with Feprazone.Experimental
Ferulic acidClonixin may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Clonixin.Approved, Investigational
FleroxacinClonixin may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Clonixin.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Clonixin is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Clonixin is combined with Fludrocortisone.Approved
FluindioneClonixin may increase the anticoagulant activities of Fluindione.Investigational
FlumequineClonixin may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Clonixin is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Clonixin is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Clonixin is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Clonixin is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Clonixin is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Clonixin is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Clonixin is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Clonixin is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Clonixin is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Clonixin.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Clonixin is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Clonixin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Clonixin is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Clonixin is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Clonixin.Approved, Nutraceutical, Vet Approved
FondaparinuxClonixin may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumClonixin may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Clonixin.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Clonixin is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Clonixin.Approved
FramycetinClonixin may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideClonixin may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateClonixin may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinClonixin may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinClonixin may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Clonixin.Approved, Withdrawn
GemifloxacinClonixin may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinClonixin may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinClonixin may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AClonixin may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Clonixin may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinClonixin may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Clonixin is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Clonixin is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Clonixin is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Clonixin is combined with HE3286.Investigational
HeparinClonixin may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Clonixin is combined with Higenamine.Investigational
HydralazineClonixin may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Clonixin.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Clonixin is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Clonixin.Approved, Investigational
Hygromycin BClonixin may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Clonixin is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Clonixin.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Clonixin.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Clonixin.Approved
IdarubicinClonixin may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxClonixin may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Clonixin.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Clonixin.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Clonixin is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Clonixin.Approved
IndenololClonixin may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Clonixin is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Clonixin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Clonixin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Clonixin.Approved, Investigational
IsepamicinClonixin may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Clonixin.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Clonixin is combined with Istaroxime.Investigational
KanamycinClonixin may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Clonixin.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Clonixin.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Clonixin.Approved
LabetalolClonixin may decrease the antihypertensive activities of Labetalol.Approved
LandiololClonixin may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Clonixin.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Clonixin.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Clonixin.Approved, Investigational
LepirudinClonixin may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanClonixin may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololClonixin may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinClonixin may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Clonixin.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Clonixin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Clonixin is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Clonixin.Approved
LonazolacThe risk or severity of adverse effects can be increased when Clonixin is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Clonixin.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Clonixin.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Clonixin is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Clonixin.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Clonixin.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Clonixin.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Clonixin.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Clonixin.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Clonixin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Clonixin is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clonixin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Clonixin is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Clonixin.Approved
MelagatranClonixin may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Clonixin is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Clonixin.Approved, Vet Approved
MepindololClonixin may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineClonixin may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Clonixin.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Clonixin.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Clonixin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Clonixin is combined with Methylprednisolone.Approved, Vet Approved
MetipranololClonixin may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Clonixin.Approved
MetoprololClonixin may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideClonixin may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinClonixin may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Clonixin.Approved
MizoribineThe risk or severity of adverse effects can be increased when Clonixin is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Clonixin.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Clonixin is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Clonixin is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Clonixin.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Clonixin.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clonixin.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Clonixin.Approved
NadololClonixin may decrease the antihypertensive activities of Nadolol.Approved
NadroparinClonixin may increase the anticoagulant activities of Nadroparin.Approved
NafamostatClonixin may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Clonixin.Approved
Nalidixic AcidClonixin may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Clonixin.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Clonixin is combined with NCX 1022.Investigational
NeamineClonixin may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololClonixin may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinClonixin may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinClonixin may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Clonixin.Approved
NetilmicinClonixin may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Clonixin is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Clonixin.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Clonixin.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Clonixin is combined with Nitroaspirin.Investigational
NorfloxacinClonixin may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Clonixin is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Clonixin.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clonixin.Approved
OlsalazineClonixin may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of can be d when Clonixin is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Clonixin.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Clonixin is combined with Orgotein.Vet Approved
OtamixabanClonixin may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Clonixin.Approved
Oxolinic acidClonixin may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololClonixin may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clonixin.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Clonixin is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Clonixin is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Clonixin.Approved
ParomomycinClonixin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Clonixin is combined with Parthenolide.Investigational
PazufloxacinClonixin may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinClonixin may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololClonixin may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateClonixin may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateClonixin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Clonixin.Approved
PhenindioneClonixin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonClonixin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Clonixin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clonixin.Approved, Investigational
PindololClonixin may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidClonixin may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinClonixin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideClonixin may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Clonixin.Approved, Investigational
Piromidic acidClonixin may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clonixin.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Clonixin is combined with Pirprofen.Experimental
Platelet Activating FactorClonixin may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinClonixin may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinClonixin may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Clonixin.Approved
PractololClonixin may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Clonixin.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Clonixin is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Clonixin is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Clonixin is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Clonixin is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Clonixin is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Clonixin is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Clonixin is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe serum concentration of Clonixin can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Clonixin is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Clonixin is combined with Propacetamol.Approved, Investigational
PropranololClonixin may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Clonixin is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Clonixin is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Clonixin.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Clonixin.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Clonixin.Vet Approved
Protein CClonixin may increase the anticoagulant activities of Protein C.Approved
Protein S humanClonixin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeClonixin may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinClonixin may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Clonixin.Investigational
PuromycinClonixin may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Clonixin.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Clonixin.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Clonixin.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Clonixin.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clonixin.Approved, Experimental, Investigational
ReviparinClonixin may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinClonixin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Clonixin is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Clonixin is combined with Risedronate.Approved, Investigational
RivaroxabanClonixin may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Clonixin.Investigational, Withdrawn
RosoxacinClonixin may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinClonixin may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinClonixin may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Clonixin.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Clonixin.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Clonixin.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Clonixin.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Clonixin.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Clonixin.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Clonixin.Approved
SemapimodThe risk or severity of adverse effects can be increased when Clonixin is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Clonixin.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Clonixin is combined with Serrapeptase.Investigational
SisomicinClonixin may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinClonixin may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Clonixin.Approved
SotalolClonixin may decrease the antihypertensive activities of Sotalol.Approved
SP1049CClonixin may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinClonixin may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinClonixin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Clonixin.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Clonixin.Investigational
StreptomycinClonixin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinClonixin may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Clonixin.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Clonixin.Approved
SulodexideClonixin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Clonixin.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Clonixin.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Clonixin is combined with Suxibuzone.Experimental
TacrolimusClonixin may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Clonixin.Approved
TalinololClonixin may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Clonixin.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Clonixin.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Clonixin.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Clonixin is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Clonixin is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Clonixin.Approved, Investigational
TemafloxacinClonixin may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Clonixin.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Clonixin is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Clonixin is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Clonixin.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Clonixin is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Clonixin.Approved
TertatololClonixin may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Clonixin.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Clonixin is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololClonixin may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Clonixin is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Clonixin is combined with Tixocortol.Approved, Withdrawn
TobramycinClonixin may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Clonixin.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Clonixin.Approved
TorasemideClonixin may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Clonixin.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Clonixin.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Clonixin.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Clonixin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Clonixin is combined with Triamcinolone.Approved, Vet Approved
TriamtereneClonixin may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Clonixin is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Clonixin.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Clonixin is combined with Triptolide.Investigational
TrovafloxacinClonixin may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinClonixin may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Clonixin is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Clonixin.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Clonixin.Investigational, Withdrawn
ValrubicinClonixin may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Clonixin.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Clonixin.Approved
WarfarinClonixin may increase the anticoagulant activities of Warfarin.Approved
XimelagatranClonixin may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clonixin.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Clonixin.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Clonixin.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Clonixin is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Clonixin.Withdrawn
Zoptarelin doxorubicinClonixin may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinClonixin may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
  1. Finch JS, DeKornfeld TJ: Clonixin: a clinical evaluation of a new oral analgesic. J Clin Pharmacol New Drugs. 1971 Sep-Oct;11(5):371-7. [PubMed:4935715]
External Links
KEGG Drug
D03555
PubChem Compound
28718
PubChem Substance
310265125
ChemSpider
26711
ChEBI
76200
ChEMBL
CHEMBL1332971
HET
6J3
Wikipedia
Clonixin
PDB Entries
5l4i
MSDS
Download (82.2 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0535 mg/mLALOGPS
logP3.59ALOGPS
logP3.42ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)1.88ChemAxon
pKa (Strongest Basic)5.37ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area62.22 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity69.8 m3·mol-1ChemAxon
Polarizability25.98 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03ea-2590000000-f577010fed0b7319669b

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyridinecarboxylic acids. These are compounds containing a pyridine ring bearing a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Pyridinecarboxylic acids and derivatives
Direct Parent
Pyridinecarboxylic acids
Alternative Parents
Aniline and substituted anilines / Toluenes / Aminopyridines and derivatives / Chlorobenzenes / Aryl chlorides / Imidolactams / Vinylogous amides / Heteroaromatic compounds / Amino acids / Secondary amines
show 8 more
Substituents
Pyridine carboxylic acid / Aniline or substituted anilines / Aminopyridine / Chlorobenzene / Toluene / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Imidolactam
show 21 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organochlorine compound, aminopyridine, pyridinemonocarboxylic acid (CHEBI:76200)

Drug created on October 21, 2015 11:14 / Updated on December 01, 2017 16:14